Virpax Pharmaceuticals, Inc. ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) ...
Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central ...
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
An expert discusses how the availability of subcutaneous (SC) immune checkpoint inhibitors (ICI) for bladder cancer impacts ...
Weekly subcutaneous administration of sabirnetug was well-tolerated in the Phase 1 study Systemic exposure following subcutaneous administration ...
AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...
The ReNEW study for dry AMD is evaluating the efficacy, safety, and pharmacokinetics of daily subcutaneous injections of ...
NIH has launched a human trial for LASSARAB, a dual-purpose vaccine targeting Lassa fever and rabies. Early animal studies ...
Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA ...
A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.
By replacing the defective gene associated with Dravet syndrome in mice, scientists successfully alleviated symptoms without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback